Company Overview and News

 
Nawaloka & Durdans join Asiri in DOC990 Joint Venture with Dialog

2018-04-26 lankabusinessonline
Apr 26, 2018 (LBO) – DOC990 operated by Digital Health (Pvt) Ltd together with Asiri Hospital Holdings on Wednesday announced the expansion of the joint venture partnership with equity investments from Nawaloka Hospitals and Ceylon Hospitals (Durdans).

 
Nawaloka Hospital opens dedicated specialist centre for channelling

2018-02-16 lankabusinessonline
Sri Lanka’s pioneer in premium private healthcare, Nawaloka Hospital PLC set another benchmark in the country’s health sector by opening its dedicated ‘Specialist Centre’ for Channelling and medical services which brings together over 500 consultants from various disciplines under the same roof.

 
Grand finale of CA Sri Lanka 53rd Annual Report Awards Competition

2017-12-06 lankabusinessonline
Commercial Bank of Ceylon PLC won the coveted ‘Cyril Gardiner Memorial Trophy’ Gold Award for Overall Excellence in Annual Financial Reporting at the grand finale of the 53rd Annual Report Awards Competition organized by the Institute of Chartered Accountants of Sri Lanka (CA Sri Lanka).

 
Eminent Chartered Accountants Tissa Bandaranayake and Ajit Jayaratne inducted to CA Sri Lanka Hall of Fame

2016-11-02 bizenglish.adaderana.lk
The Institute of Chartered Accountants of Sri Lanka (CA Sri Lanka) recently paid tribute to two eminent Chartered Accountants by inducting them to the CA Sri Lanka Hall of Fame in recognition of their exemplary contribution towards the development of the accounting profession, the business world and the country.

 
Nawaloka Cancer centre aims for the next frontier in the fight against cancer

2016-10-17 bizenglish.adaderana.lk
Pioneering private healthcare provider, Nawaoloka Hospitals, underscored the need to adopt comprehensive care, advanced diagnostic facilities and personalized counselling to address the growing national need to take the fight against cancer to the next level. In this context, Nawaloka Cancer centre brings together a team of skilled and experienced physicians, surgeons, laboratory and nursing staff along with cutting-edge facilities to provide ample care under one roof.

 
Nawaloka Hospitals announces its newly equipped Neuro-Centre

2016-07-26 bizenglish.adaderana.lk
In response to growing needs for comprehensive and compassionate care for neurological and spinal treatments, private healthcare giant, Nawaloka Hospitals in a release to media, announced that their Neurosurgical centre is now a focal point for quality care and services and best equipped for advanced treatments in significant neurological and spine illnesses.

 
Nawaloka Hospitals opens ‘Nagai’, luxury elderly-care centre

2016-07-01 bizenglish.adaderana.lk
Joint Venture with Mr. Hiromitsu Takahashi of Social Welfare Corporation Koushikai General Welfare Facility Rengesou, will provide integrated health and eldercare services to meet the different needs of the elderly

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...